Ardelyx (ARDX) Research & Development (2013 - 2026)
Ardelyx (ARDX) posted Research & Development of $20.2 million for Q1 2026, down 11.67% on a QoQ basis from $22.9 million in Q4 2025, and up 35.15% year-over-year from $14.9 million in Q1 2025.
Ardelyx (ARDX) Research & Development (2013 - 2026) Analysis & Trends
Ardelyx's Research & Development history runs 14 years deep, the most recent figure standing at $20.2 million for Q1 2026.
- Quarterly Research & Development rose 35.15% year-over-year to $20.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $76.8 million (up 35.47% YoY) and the FY2025 annual result came in at $71.5 million, up 36.72% from the prior year.
- Research & Development was $20.2 million for Q1 2026 at Ardelyx, down from $22.9 million in the prior quarter.
- Across five years, Research & Development topped out at $22.9 million in Q4 2025 and bottomed at $7.5 million in Q3 2022.
- A 5-year average of $12.6 million and a median of $10.6 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development tumbled 68.49% — and 2024, when it surged 77.26%.
- Ardelyx's Research & Development stood at $9.1 million in 2022, then advanced by 4.18% to $9.5 million in 2023, then surged by 43.49% to $13.7 million in 2024, then soared by 67.25% to $22.9 million in 2025, then retreated by 11.67% to $20.2 million in 2026.
- Business Quant data shows ARDX's Research & Development at $20.2 million in Q1 2026, $22.9 million in Q4 2025, and $18.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | Ardelyx | 1.24 Bn | 999.81 Mn | 89.66 Mn | 20.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.19 Mn |
| Dec 31, 2025 | 22.86 Mn |
| Sep 30, 2025 | 18.07 Mn |
| Jun 30, 2025 | 15.67 Mn |
| Mar 31, 2025 | 14.94 Mn |
| Dec 31, 2024 | 13.67 Mn |
| Sep 30, 2024 | 15.31 Mn |
| Jun 30, 2024 | 12.76 Mn |
| Mar 31, 2024 | 10.58 Mn |
| Dec 31, 2023 | 9.52 Mn |
| Sep 30, 2023 | 8.64 Mn |
| Jun 30, 2023 | 8.28 Mn |
| Mar 31, 2023 | 9.09 Mn |
| Dec 31, 2022 | 9.14 Mn |
| Sep 30, 2022 | 7.47 Mn |
| Jun 30, 2022 | 9.74 Mn |
| Mar 31, 2022 | 8.85 Mn |
| Dec 31, 2021 | 20.97 Mn |
| Sep 30, 2021 | 23.70 Mn |
| Jun 30, 2021 | 26.02 Mn |